Close
Back to GILD Stock Lookup

Gilead Sciences (GILD) – Company Press Releases

Oct 3, 2022 09:00 AM Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product
Sep 22, 2022 08:30 AM Gilead Joins First-of-its-Kind Public-Private Initiative to Improve Management of Viral Hepatitis in Vietnam and the Philippines
Sep 20, 2022 04:30 PM Gilead Sciences Completes Acquisition of MiroBio
Sep 16, 2022 07:00 AM Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Sep 16, 2022 06:39 AM CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Sep 15, 2022 06:21 PM WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline
Sep 13, 2022 11:28 AM Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity
Sep 7, 2022 06:05 PM Trodelvy® Significantly Improved Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in TROPiCS-02 Study
Sep 6, 2022 06:30 PM Kite’s CAR T-cell Therapy Tecartus® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
Sep 4, 2022 06:05 PM New TROPiCS-02 Data in HR+/HER2- Metastatic Breast Cancer Patients Demonstrates Progression-Free Survival Benefit of Trodelvy® Regardless of Their HER2 Status
Aug 29, 2022 04:05 PM Gilead Sciences to Present at Upcoming Investor Conferences
Aug 29, 2022 08:30 AM Gilead Demonstrates Strength of Oncology Portfolio Across Diverse Tumor Types at ESMO Congress 2022
Aug 22, 2022 01:00 AM Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
Aug 17, 2022 11:00 AM Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care
Aug 15, 2022 07:15 PM Gilead to Acquire Remaining Worldwide Rights of Trodelvy®
Aug 15, 2022 07:15 PM Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Aug 15, 2022 08:30 AM Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study
Aug 9, 2022 10:00 AM Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency
Aug 4, 2022 08:00 AM Gilead Sciences to Acquire MiroBio
Aug 2, 2022 04:01 PM Gilead Sciences Announces Second Quarter 2022 Financial Results
Jul 28, 2022 01:30 PM Biktarvy® Demonstrates High Efficacy for a Broad Range of People Initiating Treatment for HIV, Including Those With HBV Coinfection
Jul 27, 2022 07:00 AM AlloVir Announces $126.6 Million Registered Direct Offering
Jul 22, 2022 09:42 AM Kite’s CAR T-cell Therapy Tecartus® Receives Positive CHMP Opinion in Relapsed or Refractory Acute Lymphoblastic Leukemia (r/r ALL)
Jul 22, 2022 07:06 AM CHMP Adopts Positive Opinion Recommending Veklury® (Remdesivir) Receive Full Marketing Authorization for the Treatment of Patients With COVID-19
Jul 21, 2022 08:30 AM Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic
Jul 20, 2022 12:30 PM Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity
Jul 19, 2022 09:00 AM Gilead Sciences Signs New Joint Procurement Agreement with the European Commission for Veklury® (Remdesivir)
Jul 12, 2022 04:05 PM Gilead Sciences to Release Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
Jul 12, 2022 08:30 AM Gilead Sciences Appoints Deborah Telman as Executive Vice President, Corporate Affairs and General Counsel
Jun 28, 2022 06:00 AM Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
Jun 27, 2022 04:30 PM Gilead Resubmits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting HIV-1 Capsid Inhibitor
Jun 27, 2022 09:00 AM Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases
Jun 24, 2022 08:00 AM Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV
Jun 23, 2022 08:30 AM Treatment With Hepcludex® (Bulevirtide) Meets Primary Endpoint and Achieves Significant Response in Chronic Hepatitis Delta Virus at 48 Weeks
Jun 21, 2022 09:00 AM Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
Jun 6, 2022 09:00 AM Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC
Jun 4, 2022 04:00 PM Tecartus® Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell
Jun 4, 2022 09:00 AM Sub-analyses of Landmark ZUMA-7 Trial Reinforce Yescarta® CAR T-cell Therapy Superiority Over Standard of Care (SOC) as Initial Treatment for Patients With Relapsed or Refractory Large B-cell Lymphom
Jun 4, 2022 08:30 AM Everest Medicines' Licensing Partner Gilead Sciences Announces Positive Results from Phase 3 TROPiCS-02 Study of Trodelvy® in Heavily Pre-treated HR+/HER2- Metastatic Breast Cancer Patients
Jun 4, 2022 08:00 AM Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients
Jun 3, 2022 04:00 PM Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity
Jun 2, 2022 09:00 AM Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing
May 19, 2022 01:30 PM Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
May 17, 2022 04:30 PM Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
May 16, 2022 04:10 PM FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
May 16, 2022 07:30 AM Eikon Therapeutics Announces the Election of Robin L. Washington to Its Board of Directors
May 2, 2022 08:30 AM Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
Apr 28, 2022 04:02 PM Gilead Sciences Announces First Quarter 2022 Financial Results
Apr 26, 2022 06:13 PM Gilead Sciences to Present at Upcoming Investor Conferences
Apr 25, 2022 02:29 PM Veklury® (Remdesivir) is First and Only Approved Treatment for Pediatric Patients Under 12 Years of Age with COVID-19

Back to GILD Stock Lookup